• Biology of LAG3/PD1, IL-35 and Nrp1 in mouse models of cancer.

  • Impact and function of Tregs and inhibitory receptors in the several autoimmune and inflammatory disease with emphasis on models of autoimmune diabetes (NOD mouse model), EAE and asthma; development of approaches to enhance Treg stability and function; therapeutic delivery approaches to promote IL-35, Nrp1 and LAG3 function.

Selected publications:

 

Bettini M, Vignali DAA (2011). T cell-driven initiation and propagation of autoimmune diabetes. Current Opinion in Immunology 23: 754-760 [Pubmed]

Herold KC, Vignali DAA, Cooke A, Bluestone JA (2012). Type I diabetes: translating mechanistic observations into effective clinical outcomes. Nature Review Immunology 13: 243-256 [Pubmed]

Vignali DAA (2013). Interview: Immunotherapeutic manipulation of the tumor microenvironment. Immunotherapy 5: 1279-1281 [Pubmed]

Andrews LP, Marciscano AE, Drake CG, Vignali DAA (2017). LAG3 (CD223) as a cancer immunotherapy target. Immunological Reviews 276: 80-96 [Pubmed]